In this episode, Richard Austin, Paul Lebeau, and Michel Chrétien explain that the human Q152H ProPCSK9 mutation acquires an unexpected novel function: protection against ER stress and liver injury by enhancing chaperone expression.
In this episode, Olurotimi O. Mesubi explains that the discovery of oxidation of CaMKII and O-GlcNAcylation differentially increased atrial fibrillation risk in type 1 and type 2 diabetic mice, and identified a new pathway with the potential to reduce atrial fibrillation in diabetes.
Beginning in the mid-1980s, Dr. Griffin Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health, led studies demonstrating the effectiveness of the drug hydroxyurea, the first FDA-approved drug for sickle cell disease. Since then, Rodgers has worked on transplant strategies and therapies for sickle cell disease and other hemoglobinopathies while also taking on massive leadership and administrative roles at the NIH, culminating in his appointment to the directorship of the NIDDK in 2007. Watch to hear about how Malcolm Gladwell and Howard Hughes played a role in sickle cell anemia and why it’s fitting to study hematology at a diabetes- and kidney-focused institute.
In this episode, Melania Capasso explains how mTOR is hyperactivated in microglia with age and causes increased translation of inflammatory mediators, thus critically regulating microglia priming.
Persistent depolarization of β-cells leads to Gs to Gq signaling switch, explaining the differential effects of GLP-1 and GIP on insulin secretion in diabetes.